Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Google Analytics

Google Maps

Content Delivery Network

WordPress

Chief Medical Officer

Angela Genge

Chief Scientific Officer

Dan Elbaum

Founder and CEO of QurAlis

Kasper Roet

Vice President Regulatory Affairs

Bryan Boggs

Director Clinical Supply Chain

Alex Asnis, MS

Marketing and Product

Amit Jain

Director, Clinical Operations

Clarida Martinez

Engineering

Gilbert Nguyen

Director of Analytical Development and Quality Control

Huijun Tian

Finance and Administration

Kristine Kelly

Anthony Walsh

Cillian King

Johannes Fruehauf

Laia Crespo

Jeffrey Moore

Jonathan J. Fleming

Sudhir Agrawal

Anne C. Whitaker

Clifford J Woolf

Founder

Founder and CEO

Kevin Eggan

Biotechnology Companies With More Than 100 Employees

East Coast Companies With More Than 50 Employees (Top 10K)

Massachusetts Early Stage Companies With More Than $1M in Revenue

United States Early Stage Companies (Top 10K)

QurAlis is a clinical-stage biotechnology company that is developing precision medicines with genetically validated targets for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its proprietary platforms and biomarkers allow for the design and development of drugs that target disease-causing genetic alterations directly.

Droia Ventures

EQT Life Sciences

LSP Dementia Fund

Sanofi Ventures

Series B - QurAlis

Dementia Discovery Fund

Inkef

Mission BioCapital

Polaris Partners

Series A - QurAlis

Seed Round - QurAlis

Computer and Software Services and Scientific Services

Cambridge

Massachusetts

United States

North America

QurAlis

QurAlis' ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF) Phase With First Participant Dosed

QurAlis to Participate in Upcoming Investor and Industry Conferences in September

QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors

QurAlis Expands its Industry-Leading Precision Medicine Approach in Splicing Targets Beyond Neurodegeneration ...

QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores ...

Lilly gilds neuro pipeline, paying QurAlis $45M for preclinical ALS, dementia prospect

QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD

Quralis licenses QRL-204 to Lilly for up to $622M

A therapeutic candidate aimed at restoring STMN2 expression in ALS patients.

A therapeutic candidate designed to reduce hyperexcitability-induced neurodegeneration in ALS patients by opening Kv7 channels.

A platform dedicated to discovering and developing precision therapies for TDP-43-related diseases.

A platform for developing antisense oligonucleotides to modulate RNA splicing and treat diseases like ALS and FTD.

India

Asia

Bangladesh

Poland

Europe

QurAlis Corporation is a clinical-stage biotechnology company developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets.

QurAlis Corporation

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 8, 2024 10:29 AM	493d3618
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 10:29 AM	cbbdfb7a
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	1381cc69
crunchbase profile	general	Nov 25, 2024 9:42 AM	633f73c0
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 1:54 PM	c680f4fa
peers	general
news basic	general	Mar 8, 2024 10:29 AM	f2fb8b7a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

QURA

COM:QURALIS

QurAlis Corporation